Spotlight
Cancer Type
About CURE
Sign Up for eNews
- Waldenström Macroglobulinemia
- Melanoma
- Bladder Cancer
- Brain Cancer
- Breast Cancer
- Childhood Cancers
- Gastric Cancer
- Gynecologic Cancer
- Head & Neck Cancer
- Immunotherapy
- Kidney Cancer
- Leukemia
- Liver Cancer
- Lung Cancer
- Lymphoma Cancer
- Mesothelioma
- MPN
- MDS
- Myeloma
- Prostate Cancer
- Rare Cancers
- Sarcoma
- Skin Cancer
- Testicular Cancer
- Thyroid Cancer
Metastatic Triple Negative Breast Cancer: Overcoming Challenges in Diagnosis Treatment and Management : Episode 3
Second-Line Therapy for Metastatic TNBC
Shay Elkins, a patient with triple negative breast cancer, shares her experience of relapse six months post-treatment, eventually leading her to seek a second opinion for her recurring symptoms. Dr. Noor Abuhadra discusses second-line treatment options for metastatic triple negative breast cancer, emphasizing newer therapies like antibody drug conjugates and PARP inhibitors, and highlights the evolving landscape that offers hope for patients.
EP: 1.Background on Metastatic Triple Negative Breast Cancer
EP: 2.Initial Treatment Options for Metastatic TNBC
Now Viewing
EP: 3.Second-Line Therapy for Metastatic TNBC
EP: 4.ASCENT Study: Impact of Sacituzumab Govitecan on Metastatic TNBC
EP: 5.Managing Adverse Events in Patients Receiving Later Line Systemic Therapy for Metastatic TNBC
EP: 6.Overcoming Barriers to Treatment Access and Reimbursement
Related Videos
Related Content
